Johns Hopkins has discovered a small region on chromosome 2 that is associated with increased risk for attempted suicide. This small region contains four genes, including the ACP1 gene, and the researchers found more than normal levels of the ACP1 protein in the brains of people who had committed suicide. This protein is thought to influence the same biological pathway as lithium, a medication known to reduce the rate of suicidal behavior.
“We have long believed that genes play a role in what makes the difference between thinking about suicide and actually doing it,” says study leader Virginia L. Willour, Ph.D., an assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine.
Willour and her colleagues studied DNA samples from nearly 2,700 adults with bipolar disorder, 1,201 of them with a history of suicide attempts and 1,497 without. They found that those with one copy of a genetic variant in the region of chromosome 2 where ACP1 is located were 1.4 times more likely to have attempted suicide, and those with two copies were almost three times as likely.
The researchers were able to replicate their findings in another group of samples. This one comprised DNA from more than 3,000 people with bipolar disorder. By using only DNA from people with bipolar disorder, the researchers say they were able to control for mental illness and narrow in on what may cause one group to attempt suicide and another to control those urges.
Suicide is estimated to kill 1.4 percent of the U.S. population, and roughly 4.6 percent of the population has attempted suicide at least once, Willour says. Among people with bipolar disorder, 47 percent think about killing themselves while 25 percent actually try to do it, she says.
Willour says the next steps are to replicate these findings and to determine the exact biological mechanisms through which these genetic risk factors increase the risk for suicidal behavior.
“What’s promising are the implications of this work for learning more about the biology of suicide and the medications used to treat patients who may be at risk,” Willour says. “Not everyone with bipolar disorder can take lithium because of its side effects. If we could give them another option, that would be fantastic.”
The study was funded by grants from the National Institute of Mental Health and the American Foundation for Suicide Prevention.
Other Hopkins researchers who participated in the study are Fayaz Seifuddin, M.S.; Pamela B. Mahon, Ph.D.; Dubravka Jancic, Ph.D.; Mehdi Pirooznia, M.D., Ph.D.; Barbara Schweizer, R.N., B.S.; Fernando S. Goes, M.D.; Francis Mondimore, M.D.; Dean F. MacKinnon, M.D.; J. Raymond DePaulo Jr., M.D.; Peter P. Zandi, Ph.D.; and James B. Potash, M.D., M.P.H.
Read more about the study results here.